Validating the performance of the mammary sentinel lymph node team

David M. Euhus, George N. Peters, A. Marilyn Leitch, Hossein Saboorian, Dana Mathews, William Erdman, Beth Anglin, James Huth

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background and Objectives: The mammary sentinel lymph node (SLN) procedure has the potential to improve the accuracy and lower the morbidity of axillary staging in breast cancer patients, but results are closely linked to experience and can vary widely between institutions. Standardized performance measures need to be established in order to optimize the transition to SLN biopsy only. Methods: Performance data were prospectively collected for the first 156 mammary SLN procedures performed by three surgeons in our institution. Results: Seventy-five cases were required to achieve an SLN visualization rate of >80% on preoperative lymphoscintigraphy. The SLN visualization rate was 90% for the last 52 cases. Two surgeons required 25 cases before consistently achieving a ≥90% SLN identification rate in the operating room and one required 15 cases. The metastasis detection rate increased from 22% for the first 52 cases to 31% for the last 52 cases. The false negative rate for the procedure was 5%. Conclusions: The following performance criteria and benchmarks are suggested for validating the performance of the SLN team: (1) SLN visualization rate on preoperative lymphoscintigraphy ≥80%, (2) SLN identification rate in the operating room ≥90%, (3) False negative rate for the procedure 5%. Thirty procedures per surgeon were sufficient to achieve these benchmarks in our group.

Original languageEnglish (US)
Pages (from-to)209-215
Number of pages7
JournalJournal of Surgical Oncology
Volume79
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Breast
Lymphoscintigraphy
Benchmarking
Operating Rooms
Sentinel Lymph Node Biopsy
Sentinel Lymph Node
Breast Neoplasms
Neoplasm Metastasis
Morbidity
Surgeons

Keywords

  • Breast cancer
  • Learning curves
  • Lymphoscintigraphy
  • Sentinel lymph node
  • Staging

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Validating the performance of the mammary sentinel lymph node team. / Euhus, David M.; Peters, George N.; Leitch, A. Marilyn; Saboorian, Hossein; Mathews, Dana; Erdman, William; Anglin, Beth; Huth, James.

In: Journal of Surgical Oncology, Vol. 79, No. 4, 2002, p. 209-215.

Research output: Contribution to journalArticle

Euhus, David M. ; Peters, George N. ; Leitch, A. Marilyn ; Saboorian, Hossein ; Mathews, Dana ; Erdman, William ; Anglin, Beth ; Huth, James. / Validating the performance of the mammary sentinel lymph node team. In: Journal of Surgical Oncology. 2002 ; Vol. 79, No. 4. pp. 209-215.
@article{f1869a600b6b474593065e8962279837,
title = "Validating the performance of the mammary sentinel lymph node team",
abstract = "Background and Objectives: The mammary sentinel lymph node (SLN) procedure has the potential to improve the accuracy and lower the morbidity of axillary staging in breast cancer patients, but results are closely linked to experience and can vary widely between institutions. Standardized performance measures need to be established in order to optimize the transition to SLN biopsy only. Methods: Performance data were prospectively collected for the first 156 mammary SLN procedures performed by three surgeons in our institution. Results: Seventy-five cases were required to achieve an SLN visualization rate of >80{\%} on preoperative lymphoscintigraphy. The SLN visualization rate was 90{\%} for the last 52 cases. Two surgeons required 25 cases before consistently achieving a ≥90{\%} SLN identification rate in the operating room and one required 15 cases. The metastasis detection rate increased from 22{\%} for the first 52 cases to 31{\%} for the last 52 cases. The false negative rate for the procedure was 5{\%}. Conclusions: The following performance criteria and benchmarks are suggested for validating the performance of the SLN team: (1) SLN visualization rate on preoperative lymphoscintigraphy ≥80{\%}, (2) SLN identification rate in the operating room ≥90{\%}, (3) False negative rate for the procedure 5{\%}. Thirty procedures per surgeon were sufficient to achieve these benchmarks in our group.",
keywords = "Breast cancer, Learning curves, Lymphoscintigraphy, Sentinel lymph node, Staging",
author = "Euhus, {David M.} and Peters, {George N.} and Leitch, {A. Marilyn} and Hossein Saboorian and Dana Mathews and William Erdman and Beth Anglin and James Huth",
year = "2002",
doi = "10.1002/jso.10078",
language = "English (US)",
volume = "79",
pages = "209--215",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Validating the performance of the mammary sentinel lymph node team

AU - Euhus, David M.

AU - Peters, George N.

AU - Leitch, A. Marilyn

AU - Saboorian, Hossein

AU - Mathews, Dana

AU - Erdman, William

AU - Anglin, Beth

AU - Huth, James

PY - 2002

Y1 - 2002

N2 - Background and Objectives: The mammary sentinel lymph node (SLN) procedure has the potential to improve the accuracy and lower the morbidity of axillary staging in breast cancer patients, but results are closely linked to experience and can vary widely between institutions. Standardized performance measures need to be established in order to optimize the transition to SLN biopsy only. Methods: Performance data were prospectively collected for the first 156 mammary SLN procedures performed by three surgeons in our institution. Results: Seventy-five cases were required to achieve an SLN visualization rate of >80% on preoperative lymphoscintigraphy. The SLN visualization rate was 90% for the last 52 cases. Two surgeons required 25 cases before consistently achieving a ≥90% SLN identification rate in the operating room and one required 15 cases. The metastasis detection rate increased from 22% for the first 52 cases to 31% for the last 52 cases. The false negative rate for the procedure was 5%. Conclusions: The following performance criteria and benchmarks are suggested for validating the performance of the SLN team: (1) SLN visualization rate on preoperative lymphoscintigraphy ≥80%, (2) SLN identification rate in the operating room ≥90%, (3) False negative rate for the procedure 5%. Thirty procedures per surgeon were sufficient to achieve these benchmarks in our group.

AB - Background and Objectives: The mammary sentinel lymph node (SLN) procedure has the potential to improve the accuracy and lower the morbidity of axillary staging in breast cancer patients, but results are closely linked to experience and can vary widely between institutions. Standardized performance measures need to be established in order to optimize the transition to SLN biopsy only. Methods: Performance data were prospectively collected for the first 156 mammary SLN procedures performed by three surgeons in our institution. Results: Seventy-five cases were required to achieve an SLN visualization rate of >80% on preoperative lymphoscintigraphy. The SLN visualization rate was 90% for the last 52 cases. Two surgeons required 25 cases before consistently achieving a ≥90% SLN identification rate in the operating room and one required 15 cases. The metastasis detection rate increased from 22% for the first 52 cases to 31% for the last 52 cases. The false negative rate for the procedure was 5%. Conclusions: The following performance criteria and benchmarks are suggested for validating the performance of the SLN team: (1) SLN visualization rate on preoperative lymphoscintigraphy ≥80%, (2) SLN identification rate in the operating room ≥90%, (3) False negative rate for the procedure 5%. Thirty procedures per surgeon were sufficient to achieve these benchmarks in our group.

KW - Breast cancer

KW - Learning curves

KW - Lymphoscintigraphy

KW - Sentinel lymph node

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=0036202078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036202078&partnerID=8YFLogxK

U2 - 10.1002/jso.10078

DO - 10.1002/jso.10078

M3 - Article

C2 - 11920777

AN - SCOPUS:0036202078

VL - 79

SP - 209

EP - 215

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -